JP2019505210A5 - - Google Patents

Download PDF

Info

Publication number
JP2019505210A5
JP2019505210A5 JP2018537450A JP2018537450A JP2019505210A5 JP 2019505210 A5 JP2019505210 A5 JP 2019505210A5 JP 2018537450 A JP2018537450 A JP 2018537450A JP 2018537450 A JP2018537450 A JP 2018537450A JP 2019505210 A5 JP2019505210 A5 JP 2019505210A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
nucleotide sequence
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018537450A
Other languages
English (en)
Japanese (ja)
Other versions
JP6820935B2 (ja
JP2019505210A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/050229 external-priority patent/WO2017125844A1/en
Publication of JP2019505210A publication Critical patent/JP2019505210A/ja
Publication of JP2019505210A5 publication Critical patent/JP2019505210A5/ja
Application granted granted Critical
Publication of JP6820935B2 publication Critical patent/JP6820935B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018537450A 2016-01-19 2017-01-16 がんワクチン Expired - Fee Related JP6820935B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662280636P 2016-01-19 2016-01-19
US62/280,636 2016-01-19
US201662419190P 2016-11-08 2016-11-08
US62/419,190 2016-11-08
PCT/IB2017/050229 WO2017125844A1 (en) 2016-01-19 2017-01-16 Cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021000428A Division JP2021061851A (ja) 2016-01-19 2021-01-05 がんワクチン

Publications (3)

Publication Number Publication Date
JP2019505210A JP2019505210A (ja) 2019-02-28
JP2019505210A5 true JP2019505210A5 (enExample) 2020-02-20
JP6820935B2 JP6820935B2 (ja) 2021-01-27

Family

ID=57960563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018537450A Expired - Fee Related JP6820935B2 (ja) 2016-01-19 2017-01-16 がんワクチン
JP2021000428A Pending JP2021061851A (ja) 2016-01-19 2021-01-05 がんワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021000428A Pending JP2021061851A (ja) 2016-01-19 2021-01-05 がんワクチン

Country Status (22)

Country Link
US (3) US10251944B2 (enExample)
EP (2) EP3733201A1 (enExample)
JP (2) JP6820935B2 (enExample)
KR (2) KR20200109395A (enExample)
CN (1) CN108778321A (enExample)
AU (1) AU2017208848A1 (enExample)
BR (1) BR112018013967A2 (enExample)
CA (1) CA2954892A1 (enExample)
CO (1) CO2018007442A2 (enExample)
DK (1) DK3405212T3 (enExample)
ES (1) ES2811523T3 (enExample)
HU (1) HUE051722T2 (enExample)
IL (2) IL260321B (enExample)
MX (1) MX2018008797A (enExample)
PH (1) PH12018501532A1 (enExample)
PL (1) PL3405212T3 (enExample)
PT (1) PT3405212T (enExample)
RU (2) RU2718663C2 (enExample)
SG (1) SG11201805621SA (enExample)
SI (1) SI3405212T1 (enExample)
TW (3) TWI654302B (enExample)
WO (1) WO2017125844A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018204760A1 (en) * 2017-05-05 2018-11-08 David Weiner Ctla4 antibodies and vaccine combinations and use of same for immunotherapy
CA3222077A1 (en) * 2021-06-09 2022-12-15 Dana Michel A conjugate

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
CA1341423C (en) 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
NZ214716A (en) 1985-01-07 1989-04-26 Syntex Inc 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5817491A (en) 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
AU671971B2 (en) 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU703769B2 (en) 1996-01-05 1999-04-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Mesothelium antigen and methods and kits for targeting it
US7375183B1 (en) 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
JP2001510440A (ja) 1996-03-20 2001-07-31 スローン―ケタリング・インスティテュート・フォー・キャンサー・リサーチ ムチン接合体ペプチドワクチン
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
EP0841396B2 (en) 1996-10-01 2012-04-11 Geron Corporation Human telomerase catalytic subunit
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20050013825A1 (en) 1997-04-18 2005-01-20 Geron Corporation Vaccine containing the catalytic subunit of telomerase for treating cancer
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US6962790B1 (en) 1998-09-23 2005-11-08 University Of Massachusetts Medical Center Predictive assay for immune response
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6472028B1 (en) 1999-08-12 2002-10-29 Joseph Frazzitta Method of producing a high gloss coating on a printed surface
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB9930359D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
AU2001241533A1 (en) 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
AU2001282290A1 (en) 2000-08-17 2002-03-04 University Of Wales College Of Medicine Htert-immortalised cell lines, their preparation and use
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
WO2003038047A2 (en) 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
TWI228718B (en) 2001-11-05 2005-03-01 Tdk Corp Manufacturing method and device of mold plate for information medium
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
WO2004006837A2 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
DK1711518T3 (da) 2004-01-23 2010-04-06 Angeletti P Ist Richerche Bio Vaccinebærere for chimpanse-adenovirus
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
JP4088328B2 (ja) * 2004-12-28 2008-05-21 第一化学薬品株式会社 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
CA2652310A1 (en) 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
EP1994942A1 (en) 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
US8362209B2 (en) 2007-08-23 2013-01-29 University Of Medicine And Dentistry Of New Jersey Telomerase reverse transcriptase variant
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CN101920009B (zh) 2010-03-06 2012-08-08 河北医科大学 一种用于预防和治疗肿瘤的疫苗
EP2714081A4 (en) * 2011-05-27 2015-09-09 Cytocure Llc METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
AR087380A1 (es) 2011-07-27 2014-03-19 Baylor Res Inst Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
US8523590B2 (en) * 2011-07-29 2013-09-03 General Electric Company Cable system and methods of assembling a cable system
CA2844500C (en) * 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
CA2871711A1 (en) * 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
US10184216B2 (en) * 2012-07-18 2019-01-22 Thomas Urbanek Advantageous detectable warning area and methods of forming the same
WO2014127296A1 (en) * 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
MX369709B (es) 2013-03-15 2019-11-19 Univ Pennsylvania Vacunación mejorada contra tirosinasa.
CA2928908C (en) * 2013-11-01 2021-01-12 Pfizer Inc. Vectors for expression of prostate-associated antigens
WO2015173764A1 (en) 2014-05-15 2015-11-19 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors

Similar Documents

Publication Publication Date Title
JP2019507180A5 (enExample)
US20200323964A1 (en) Peptides and nanoparticles for intracellular delivery of mrna
CN103304638B (zh) 具有抗肿瘤活性的pd-l1亲和肽及其应用
JP2016501829A5 (enExample)
JP2019505210A5 (enExample)
JP2013172743A5 (enExample)
JP2017537627A5 (enExample)
JP2016053091A5 (enExample)
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
JP2017524348A5 (enExample)
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JP2017006120A5 (enExample)
JP2015096070A5 (enExample)
JP2018509936A5 (enExample)
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2017514522A5 (enExample)
JP2017510297A5 (enExample)
IN2014DN09963A (enExample)
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
JP2012102105A5 (enExample)
RU2018126487A (ru) Противораковые вакцины
JP2019534317A5 (enExample)
JP2014139185A5 (enExample)